Structure of an interdisciplinary pituitary outpatient care unit at the University Hospital of Leipzig and results for treatment of prolactin and growth hormone secreting pituitary tumors;Arbeitsweise einer interdisziplinären neurochirurgisch- endokrinologischen sprechstunde für Hypophysentumoren am Universitätsklinikum Leipzig und ergebnisse der behandlung von hormonaktiven hypophysenadenomen

Medizinische Klinik

Volumn 100, Issue 4, 2005, Pages 173-179

  Wiesner, Tobias D ^a   Trantakis, Christos ^a   Meixensberger, Jürgen ^a   Koch, Christian A ^a   Zimmer, Claus ^a   Paschke, Ralf ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Acromegaly; Functioning pituitary adenoma; Interdisciplinary approach; Neurosurgery; Prolactinoma

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; GROWTH HORMONE; HORMONE; OCTREOTIDE; PROLACTIN;

ACROMEGALY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HEALTH CARE QUALITY; HUMAN; HYPOPHYSIS ADENOMA; INTERDISCIPLINARY COMMUNICATION; INTERMETHOD COMPARISON; MICROADENOMA; NEUROSURGERY; OUTPATIENT; PROLACTINOMA; TREATMENT PLANNING; TUMOR REGRESSION; TUMOR VOLUME; UNIVERSITY HOSPITAL;

ACROMEGALY; ADENOMA; ADULT; AGE FACTORS; COMBINED MODALITY THERAPY; DOPAMINE AGONISTS; FEMALE; FOLLOW-UP STUDIES; GERMANY; GROWTH HORMONE; HOSPITAL UNITS; HUMANS; INTERDISCIPLINARY COMMUNICATION; MALE; MIDDLE AGED; OUTPATIENTS; PATIENT CARE TEAM; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; SEX FACTORS; TIME FACTORS;

EID: 17744373147     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-005-1018-0     Document Type: Article

References (40)

1. Hardy J. Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg 1969;16:185-217.
2. Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf) 1994;41:359-64.
3. Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:4054-8.
4. Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994;41:95-102.
5. Swearingen B, Barker FG, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-26.
6. Sheppard MC. Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 2003;58:387-99.
7. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998;89:353-8.
8. Kreutzer J, Vance ML, Lopes MB, et al. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001;86:4072-7.
9. Sheaves R, Jenkins P, Blackburn P, et al. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 1996;45:407-13.
10. Fahlbusch R, Honegger J, Buchfelder M. Evidence supporting surgery as treatment of choice for acromegaly. J Endocrinol 1997;155:Suppl 1:S53-5.
11. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-9.
12. Abe T, Ludecke D. Effects of preoperative octreotide treatment on different subtypes of 90 GH secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 2001;145:137-45.
13. Costa AC, Rossi A, Martinelli CE, et al. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 2002;87:3142-7.
14. Melmed S, Ho K, Klibanski A, et al. Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995;80:3395-102.
15. Katznelson L, Klibanski A. Prolactin audits disorders. In: Becker KL, ed. Principles and practice of endocrinology and metabolism. Philadelphia: Lippincott Williams & Wilkins, 2001:145-53.
16. Kovacs K, Horvath E. Pathology of pituitary tumors. Endocrinol Metab Clin North Am 1987;16:529-51.
17. Tabarin A, Carrie F, Ronci N, et al. Dopamine D 2 receptor gene expression in growth hormone-producing pituitary adenomas. Proceedings of the 4th International Pituitary Congress, San Diego, CA, June 16-18. 1996.abstract H5.
18. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83:374-8.
19. Cozzi R, Attanasio R, Barausse M, et al. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 1998;139:516-21.
20. Merza Z. Modern treatment of acromegaly. Postgrad Med J 2003;79:189-93.
21. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342:1171-7.
22. Drake WM, Parkinson C, Akker SA, et al. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. Eur J Endocrinol 2001;145:451-6.
23. Herman B, Zib K, Scarlett JA, et al. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 2000;85:2958-61.
24. Colao A, Annunziato L, Lombardi G. Treatment of prolactinomas. Ann Med 1998;30:452-9.
25. Klingmüller D, Saller B, Quabbe HJ. Diagnostik von Hypopysenadenomen. Dtsch Ärztebl 2001;98:3053-9.
26. Schlechte J. Prolactinoma. N Engl J Med 2003;21:2035-41.
27. St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 1996;44:305-9.
28. Schofl C, Schofl-Siegert B, Karstens J, et al. Falsely low serum prolactin in two cases of invasive macroprolactinoma. Pituitary 2002;5:261-5.
29. Elster AD. Modern imaging of the pituitary. Radiology 1993;187:1-14.
30. Vance ML. Medical treatment of functional pituitary tumors. Neurosurg Clin N Am 2003;14:81-7.
31. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994;331:904-9.
32. De Luis L, Becerra A, Lahera M, et al. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. J Endocrinol Invest 2000;23:428-34.
33. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-9.
34. Brabant G, von zur Mühlen A, Wüster C, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 2003;60:53-60.
35. Biermasz NR, van Dulken D, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 2000;85:2476-82.
36. Aron DC, Tyrrell JB, Wilson CB. Pituitary tumors. Current concepts in diagnosis and management. West J Med 1995;162:340-52.
37. Molitch ME, Thorner MO, Wilson C. Management of prolactinomas. J Clin Endocrinol Metab 1997;82:996-1000.
38. Molitch ME. Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 1999;28:143-69, vii.
39. Molitch ME. Diagnosis and treatment of prolactinomas. Adv Intern Med 1999;44:117-53.
40. Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am 1992;21:877-901.